Immutep

This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Immutep" – news · newspapers · books · scholar · JSTOR (December 2015) (Learn how and when to remove this message)

Immutep Ltd

Company type	Public
Traded as	Nasdaq: IMMP ASX: IMM
Industry	Biotechnology
Founded	2001
Headquarters	Sydney, Australia Leipzig, Germany
Key people	Marc Voigt (CEO) Frédéric Triebel (Chief Scientific and Medical Officer)
Products	IMP321, GSK2831781, CVac LAG-3 Immunotherapy
Website	www.immutep.com

Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.

Prima currently has three main products in its pipeline, all acquired with Immutep:

Eftilagimod alpha, (lab name: IMP321) which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.

IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.

IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis